Theradiag, a French company that specializes in in vitro diagnostics and theranostics, has entered into a partnership agreement with Biogen to provide its Lisa Tracker kits to monitor patients treated with Biogen’s infliximab biosimilar Flixabi, which was approved in Europe in 2016.
Theradiag, a French company that specializes in in vitro diagnostics and theranostics (targeted therapy based on targeted diagnostic tests), has entered into a partnership agreement with Biogen to provide its Lisa Tracker kits to monitor patients treated with Biogen’s infliximab biosimilar Flixabi, which was approved in Europe in 2016.
The partnership will allow Biogen to supply Lisa Tracker monitoring kits in France and other European countries to optimize the treatment of patients receiving the biosimilar. Flixabi is indicated for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriasis, and psoriatic arthritis. Under the agreement, Theradiag will be Biogen’s preferred supplier of infliximab monitoring kits. Theradiag will also handle implementation, provide training to laboratories in how to use the kits, and follow up on clinician requests concerning monitoring.
Lisa Tracker kits are used to monitor patients taking biotherapies for diseases ranging from gastroenterology, rheumatology, and dermatology to oncology. The kits allow clinicians to simultaneously monitor patients’ trough plasma levels of 3 parameters within 3 hours of reaction from a serum sample in order to anticipate, optimize, and better manage patients’ treatment with infliximab:
Consensus statements support therapeutic drug monitoring (TDM) used to guide and optimize anti-TNF therapy in IBD, particularly in situations of treatment failure. One such statement, issued by the Australian Inflammatory Bowel Disease Consensus Working Group and other international experts, recommended TDM of anti-TNF agents upon treatment failure, following successful treatment induction, and when contemplating a drug holiday.
However, the group said there is inconsistent evidence for proactive TDM, and therefore advised that TDM should be performed for patients in stable remission only if results are likely to impact clinical management.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.